Health and Healthcare

Thursday's Top Biotech and Medical Stocks

From BioHealth Investor

Biotechnology

PRAECIS PHARMA [PRCS] +144.51%
FERMAVIR PHARMACEUTL [FMVR.OB] +28.00%
POLYMEDIX INC [PYMX.OB] +23.08%
ACCENTIA BIOPHARMACE [ABPI] +17.59%
REXAHN PHARMACEUTICL [RXHN.OB] +17.39%

Diagnostic Substances

IMMUNOMEDICS INC [IMMU] +13.59%
AVALON PHARMACEUTIC [AVRX] +12.50%
ASPENBIO PHARMA INC [APNB.OB] +10.84%
REMOTEMDX INC [RMDX.OB] +7.75%
EPIX PHARMACEUTICALS [EPIX] +5.22%

Drug Delivery

BENTLEY PHARMACEUTIC [BNT] +9.18%
EMISPHERE TECH [EMIS] +6.63%
IOMED INC [IOX] +4.91%
SKYEPHARMA PLC [SKYE] +2.67%
NOVADEL PHARMA INC [NVD] +2.61%

Drug Manufacturers

PLANET TECHS INC [PLNT.OB] +33.33%
SEPRACOR INC [SEPR] +8.59%
COLLAGENEX PHARM I [CGPI] +4.90%
ALLOS THERAPEUTICS [ALTH] +2.94%
INTERPHARM HLDGS INC [IPA] +2.93%

Medical Appliances & Equipment

SYNERON MEDICAL LTD. [ELOS] +8.56%
ALPHA PRO TECH [APT] +5.30%
SPECTRANETICS CP T [SPNC] +5.22%
CELSION CORP [CLN] +5.13%
THERAGENICS CORP [TGX] +4.76%

Medical Instruments & Supplies

ENPATH MED INC [NPTH] +10.00%
ELECTRO-OPTICAL SCIE [MELA] +8.19%
ANGEION CORP [ANGN] +7.07%
CRYOCOR, INC. [CRYO] +5.58%
NEUROMETRIX, INC. [NURO] +4.56%

Medical Laboratories & Research

BIOFORCE NANOSCIENCE [BFNH.OB] +21.12% $0
MEDASORB TECHNOLOGS [MSBT.OB] +14.75% $0
ERESEARCHTECHNOLOG [ERES] +7.79% $632.6 M
ALLIANCE IMAGING INC [AIQ] +2.02% $531.8 M
PSYCHEMEDICS NEW [PMD] +1.60%

http://www.biohealthinvestor.com/

ALERT: Take This Retirement Quiz Now  (Sponsored)

Take the quiz below to get matched with a financial advisor today.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Take the retirement quiz right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.